These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22655314)

  • 1. Research. 'Superinfected' have more potent antibody response to HIV.
    AIDS Policy Law; 2012 May; 27(6):3. PubMed ID: 22655314
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV superinfection in women may boost immune response.
    Rose S
    Expert Rev Anti Infect Ther; 2012 May; 10(5):525. PubMed ID: 22702314
    [No Abstract]   [Full Text] [Related]  

  • 3. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.
    Smith DM; Strain MC; Frost SD; Pillai SK; Wong JK; Wrin T; Liu Y; Petropolous CJ; Daar ES; Little SJ; Richman DD
    Virology; 2006 Nov; 355(1):1-5. PubMed ID: 16962152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection.
    Forthal DN; Landucci G; Chohan B; Richardson BA; McClelland RS; Jaoko W; Blish C; Overbaugh J
    J Acquir Immune Defic Syndr; 2013 May; 63(1):31-3. PubMed ID: 23344546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection.
    Ssemwanga D; Doria-Rose NA; Redd AD; Shiakolas AR; Longosz AF; Nsubuga RN; Mayanja BN; Asiki G; Seeley J; Kamali A; Ransier A; Darko S; Walker MP; Bruno D; Martens C; Douek D; Porcella SF; Quinn TC; Mascola JR; Kaleebu P
    J Infect Dis; 2018 Apr; 217(10):1530-1534. PubMed ID: 29579256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.
    Serwanga J; Ssemwanga D; Muganga M; Nakiboneka R; Nakubulwa S; Kiwuwa-Muyingo S; Morris L; Redd AD; Quinn TC; Kaleebu P;
    Vaccine; 2018 Jan; 36(4):578-586. PubMed ID: 29274699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection.
    Basu D; Xiao P; Ende Z; Bere A; Britt WJ; Mulenga J; Kilembe W; Allen SA; Derdeyn CA; Hunter E
    Virology; 2014 Aug; 462-463():295-8. PubMed ID: 25004405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response.
    Cortez V; Odem-Davis K; McClelland RS; Jaoko W; Overbaugh J
    PLoS Pathog; 2012; 8(3):e1002611. PubMed ID: 22479183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 10. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 11. Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load.
    Hasselrot K; Bratt G; Hirbod T; Säberg P; Ehnlund M; Lopalco L; Sandström E; Broliden K
    AIDS; 2010 Jan; 24(1):35-43. PubMed ID: 19779318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pathway to HIV-1 neutralization breadth.
    Smith SA; Derdeyn CA
    Nat Med; 2015 Nov; 21(11):1246-7. PubMed ID: 26540383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.
    Blish CA; Dogan OC; Derby NR; Nguyen MA; Chohan B; Richardson BA; Overbaugh J
    J Virol; 2008 Dec; 82(24):12094-103. PubMed ID: 18842728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immunity to HIV-1: neutralization and beyond.
    Huber M; Trkola A
    J Intern Med; 2007 Jul; 262(1):5-25. PubMed ID: 17598812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
    Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
    Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia.
    Günthard HF; Huber M; Kuster H; Shah C; Schüpbach J; Trkola A; Böni J
    Clin Infect Dis; 2009 Jun; 48(11):e117-20. PubMed ID: 19382874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

  • 20. Study describes onset of broadly neutralizing antibody responses in HIV-infected individuals.
    von Bubnoff A
    IAVI Rep; 2011; 15(1):23. PubMed ID: 21449508
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.